Tirzepatide: The Complete Guide (2026)

Tirzepatide is one of the most-studied metabolic peptides of the last decade. Since its approval as Mounjaro (2022) and Zepbound (2023), it has become a reference point for a new class of dual-receptor agonist compounds. This guide covers what tirzepatide is, how it works at the receptor level, what the major clinical trials found, how it compares to semaglutide and retatrutide, and what the research-grade and compounded sourcing landscape looks like as of 2026.

This is an informational and research reference. It does not constitute medical advice, and nothing here is a treatment recommendation or dosing instruction for human use.

What Is Tirzepatide?#

Tirzepatide is a synthetic 39-amino acid peptide that acts as a dual agonist at two incretin receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). It was developed by Eli Lilly and received FDA approval in May 2022 as Mounjaro for type 2 diabetes, and in November 2023 as Zepbound for chronic weight management.

In the research and peptide community, tirzepatide is also available as a synthesized research-grade peptide from laboratory suppliers. This version is not FDA-approved for any use and is sold for in-vitro and laboratory research only. The compound is identical in amino acid sequence to the FDA-approved drug but is produced under vendor-level quality controls rather than pharmaceutical GMP standards.

The dual-receptor mechanism is what distinguishes tirzepatide from earlier GLP-1 agonists such as semaglutide, liraglutide, and exenatide. By engaging both GIP and GLP-1 receptors, tirzepatide produces effects through two complementary signaling pathways simultaneously — a design that the SURMOUNT and SURPASS trial programs demonstrated produces meaningfully greater glycemic and weight outcomes than single GLP-1 agonism alone.

How Tirzepatide Works#

GLP-1 Receptor Agonism#

Glucagon-like peptide-1 is an incretin hormone secreted by L-cells in the small intestine in response to food intake. Its main physiological effects include stimulating glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite centrally via hypothalamic GLP-1 receptors. GLP-1 native half-life is approximately 2 minutes due to rapid DPP-4 degradation; synthetic agonists like semaglutide and the GLP-1 component of tirzepatide are engineered to resist this degradation and extend receptor engagement.

GIP Receptor Agonism#

Glucose-dependent insulinotropic polypeptide (GIP) is secreted by K-cells in the duodenum and proximal jejunum. It was historically characterized as a redundant incretin, but research in the 2010s–2020s clarified that GIPR agonism plays a distinct and complementary role in energy homeostasis — including effects on adipose tissue, bone metabolism, and potentially additive or synergistic insulin secretion when combined with GLP-1 signaling. The contribution of GIPR agonism to tirzepatide's weight and metabolic outcomes remains an active area of study.

Why Dual Agonism Matters#

Single-axis GLP-1 agonism (semaglutide, liraglutide) produces significant metabolic effects but is subject to tolerability ceiling effects — nausea and GI side effects often limit dose escalation. The dual mechanism in tirzepatide appears to distribute the receptor load across two systems, which may explain why SURMOUNT-1 participants at the highest tirzepatide doses achieved greater weight reduction than any published semaglutide trial at the time (Jastreboff et al., NEJM 2022). Researchers studying metabolic peptides track the GIPR/GLP-1R co-agonism model as a framework for understanding why dual and triple-agonist designs outperform single-agonist compounds.

Half-Life and Dosing Interval#

Tirzepatide has a terminal elimination half-life of approximately 5 days, supporting once-weekly administration. This is similar to semaglutide's half-life profile (approximately 7 days for the 2.4 mg formulation) and distinguishes both from daily-injection compounds like liraglutide (13 hours).

Benefits and Trial Results#

The SURMOUNT and SURPASS clinical trial programs are the primary evidence base for tirzepatide's metabolic effects. Both programs were conducted in humans under FDA oversight; what follows summarizes reported outcomes for research context.

SURPASS Program (Type 2 Diabetes)#

The SURPASS trials (SURPASS-1 through SURPASS-5, plus SURPASS-CVOT) evaluated tirzepatide across a range of type 2 diabetes patient populations and comparator regimens. Key reported findings include:

• SURPASS-2: tirzepatide at 10 mg and 15 mg produced significantly greater HbA1c reductions than semaglutide 1 mg over 40 weeks (Frías et al., NEJM 2021).
• SURPASS-3: tirzepatide demonstrated non-inferiority to insulin degludec on HbA1c reduction, with weight reduction advantages (Ludvik et al., Lancet 2021).
• Across the SURPASS program, tirzepatide at 15 mg produced mean HbA1c reductions of approximately 2.0–2.3 percentage points from baseline depending on comparator arm (FDA Drug Trials Snapshots: Mounjaro).

SURMOUNT Program (Obesity / Chronic Weight Management)#

The SURMOUNT trials evaluated tirzepatide in adults with obesity (BMI ≥30) or overweight (BMI ≥27 with at least one weight-related comorbidity) without type 2 diabetes.

• SURMOUNT-1: At the highest dose (15 mg), participants lost a mean of approximately 20.9% of body weight over 72 weeks vs. approximately 3.1% for placebo (Jastreboff et al., NEJM 2022). This was the highest mean weight reduction reported in any pharmacological obesity trial at the time of publication.
• SURMOUNT-2: Evaluated tirzepatide in adults with type 2 diabetes and obesity; reported meaningful weight reduction alongside glycemic improvement (Jastreboff et al., Lancet 2023).

These are trial-population averages reported under controlled conditions. Individual outcomes vary substantially based on baseline characteristics, adherence, and concurrent lifestyle factors.

Evidence Tier Note#

The SURPASS and SURMOUNT results are Phase 3 randomized controlled trial data, the highest level of clinical evidence. They apply to the FDA-approved formulation under prescription medical supervision. Research-grade tirzepatide is not evaluated in these trials and is not approved for any therapeutic use.

Dosing and Titration#

Prescription Titration Protocol (Mounjaro / Zepbound)#

The FDA-approved prescribing information specifies a starting dose and a slow titration schedule designed to minimize GI side effects. The standard approach as reported in the prescribing label begins at 2.5 mg once weekly for the first four weeks, then escalates in 2.5 mg increments at 4-week intervals as tolerated, up to a maximum of 15 mg once weekly.

The titration schedule reported in the Mounjaro/Zepbound prescribing information:

• Weeks 1–4: 2.5 mg once weekly
• Weeks 5–8: 5 mg once weekly
• Weeks 9–12: 7.5 mg once weekly
• Weeks 13–16: 10 mg once weekly
• Weeks 17–20: 12.5 mg once weekly
• Week 21 onward: 15 mg once weekly (maximum approved dose)

Not all patients reach 15 mg; maintenance at lower doses is common based on tolerability and clinical response.

Reported Research Ranges#

Research literature on tirzepatide administration in preclinical and human research contexts has examined doses in the 2.5–15 mg weekly range, consistent with the clinical titration above. Some researchers have explored lower starting points ("microdose" protocols beginning at 0.5–1 mg) to assess tolerability and dose-response curves in specific populations, though this is outside the FDA-approved protocol and is not validated by Phase 3 data.

This section is for research reference only and does not constitute dosing instructions for human use.

Converting Milligrams to Units for Compounded Vials#

Researchers working with compounded or lyophilized tirzepatide frequently need to convert a milligram dose target to injection units when drawing from a reconstituted vial. The calculation depends on two variables: the total amount of peptide in the vial (mg) and the volume of bacteriostatic water used for reconstitution (mL).

The general formula: units to draw = (dose in mg ÷ total vial mg) × (reconstitution volume in mL × 100)

Example: A 10 mg vial reconstituted with 1 mL bacteriostatic water produces a concentration of 10 mg/mL. A 2.5 mg research dose requires drawing 0.25 mL, or 25 units on a standard U-100 insulin syringe.

Example: The same 10 mg vial reconstituted with 2 mL bacteriostatic water produces 5 mg/mL. A 2.5 mg dose requires 0.5 mL, or 50 units.

Knowing your reconstitution volume before drawing is essential for accurate measurement. A future interactive calculator will handle this math — for now, apply the formula above.

Microdose Tirzepatide — Research Context#

"Microdosing" tirzepatide — using doses substantially below the standard 2.5 mg starting point — has attracted research and clinical interest as a potential tolerability strategy and as a protocol for examining dose-response relationships at lower receptor occupancy. Reported microdose ranges in online research communities and some compounding prescriptions have included 0.25–1 mg weekly, with a slow step-up titration over many weeks rather than the 4-week intervals in the approved protocol.

The evidence base for microdosing as a formal protocol is limited compared to the standard titration schedule. It is not part of the FDA-approved labeling. Researchers and clinicians exploring this approach should treat it as investigational.

How to Reconstitute Tirzepatide (Research Use)#

Research-grade tirzepatide arrives as a lyophilized (freeze-dried) white or off-white powder sealed in a sterile vial. Before use in research applications, it must be reconstituted with bacteriostatic water (BAC water). The following describes the laboratory reconstitution procedure for research use only.

Materials needed: tirzepatide lyophilized vial, bacteriostatic water for injection (multi-dose vials), appropriate syringes, alcohol swabs, sterile conditions.

Procedure:

1. Wipe both vial stoppers with a fresh alcohol swab and allow to dry.
2. Draw the intended volume of bacteriostatic water into the syringe. Standard research protocols use 1 mL or 2 mL per vial, depending on the target concentration.
3. Insert the syringe into the tirzepatide vial at an angle and inject the BAC water slowly along the vial wall — avoid directing the stream directly onto the powder, which can cause foaming and peptide degradation.
4. Do not shake. Gently roll or swirl the vial until the powder is fully dissolved. The solution should be clear and colorless.
5. Label the vial with the compound name, concentration, date of reconstitution, and lot number from the COA.
6. Store reconstituted tirzepatide refrigerated at 2–8°C. Most peptide suppliers recommend using reconstituted material within 30 days; some cite up to 60 days refrigerated with bacteriostatic water preservation. Check vendor storage guidance.

Research note: lyophilized tirzepatide peptide can be stored at -20°C or lower before reconstitution. Minimize freeze-thaw cycles after reconstitution.

Side Effects and Safety Profile#

The side-effect profile of tirzepatide is drawn from the SURPASS and SURMOUNT trial programs and the FDA-approved prescribing information for Mounjaro and Zepbound. This applies to the prescription product under medical supervision.

Common GI Side Effects#

Gastrointestinal effects are the most frequently reported adverse events across tirzepatide trials. These are generally dose-dependent and most common during dose escalation periods.

• Nausea: reported in approximately 12–18% of trial participants at doses ≥5 mg, compared to 3–8% with placebo, varying by trial and dose arm (FDA Drug Trials Snapshots: Mounjaro).
• Diarrhea: reported in approximately 12–17% at higher doses (FDA Drug Trials Snapshots: Mounjaro).
• Vomiting: reported in approximately 5–9% (FDA Drug Trials Snapshots: Mounjaro).
• Constipation: reported in approximately 5–8% (FDA Drug Trials Snapshots: Mounjaro).
• Decreased appetite: reported by a substantial proportion of participants and is mechanistically related to therapeutic effect.

GI effects typically peak during the first weeks of a new dose level and attenuate with continued use. Slow titration is the primary mitigation strategy in the clinical protocol.

Serious but Less Common Effects#

The prescribing information for tirzepatide (Mounjaro/Zepbound) carries warnings and precautions for the following, which have been identified in clinical data or are class-wide concerns:

• Thyroid C-cell tumors: observed in rodent studies at all doses. Relevance to humans is unknown, but tirzepatide carries a boxed warning for this risk, and it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) (FDA: Zepbound approval and prescribing information).
• Pancreatitis: cases have been reported; discontinue if pancreatitis is suspected.
• Hypoglycemia: particularly when used in combination with insulin or insulin secretagogues.
• Acute kidney injury: often secondary to nausea, vomiting, and reduced fluid intake.
• Diabetic retinopathy complications: observed in the SURPASS-3 trial in the context of rapid HbA1c reduction (Ludvik et al., Lancet 2021).
• Gallbladder disease: cases of cholelithiasis and cholecystitis reported.

YMYL Note#

Tirzepatide is a prescription medication with a known serious adverse event profile. This summary is for research background only. Any human use requires medical supervision by a licensed prescriber familiar with the patient's full history and current medications.

Tirzepatide vs Semaglutide#

Semaglutide (Semaglutide) and tirzepatide are the most widely compared GLP-1-class compounds because both are FDA-approved, both are available in research-grade form, and direct head-to-head trial data exists (SURPASS-2).

Mechanism. Semaglutide is a GLP-1 receptor agonist only. Tirzepatide adds GIP receptor co-agonism. This is the core structural difference and the primary reason researchers hypothesize tirzepatide's superior efficacy in weight reduction.

Weight reduction in trials. SURMOUNT-1 reported a mean weight loss of approximately 20.9% at tirzepatide 15 mg vs. approximately 3.1% for placebo (Jastreboff et al., NEJM 2022). The STEP 1 trial for semaglutide 2.4 mg reported approximately 14.9% mean weight loss vs. placebo (Wilding et al., NEJM 2021). These trials were conducted in different populations and are not a direct head-to-head comparison; the SURPASS-2 trial was.

Direct comparison (SURPASS-2). Tirzepatide 10 mg and 15 mg produced statistically significantly greater HbA1c reduction than semaglutide 1 mg over 40 weeks in adults with type 2 diabetes (Frías et al., NEJM 2021). Weight reduction was also greater with tirzepatide at both doses. Semaglutide 1 mg is a diabetes-indication dose, not the obesity-indication 2.4 mg dose, which is a relevant limitation when interpreting this comparison.

Side effect profile. Both compounds produce similar GI side effect patterns (nausea, diarrhea, vomiting) that are dose-dependent and manageable with slow titration. Rates appear broadly comparable between the two compounds in clinical trial data; some analyses suggest slightly higher nausea rates with tirzepatide at peak doses, though this is not consistent across all studies (Frías et al., NEJM 2021).

Cost and availability. At the prescription level, both drugs are priced at similar list prices in the US market, with access heavily dependent on insurance coverage and telehealth program pricing. At the research-grade level, pricing is broadly similar per milligram across comparable vendors.

When researchers choose semaglutide over tirzepatide. Single-agonist mechanistic studies, GLP-1R-specific signaling research, and protocols requiring a longer-established compound may favor semaglutide. The compound also has a substantially longer clinical research history (liraglutide data from 2010s, semaglutide Phase 3 from 2018 onward).

When researchers choose tirzepatide over semaglutide. Dual-agonist mechanism studies, GIPR co-signaling research, protocols tracking the GIP/GLP-1 interaction, and comparative efficacy work relative to single-agonist controls.

Tirzepatide vs Ozempic#

Ozempic is the diabetes-indication brand name for semaglutide 0.5 mg, 1 mg, and 2 mg weekly injection. Wegovy is the obesity-indication brand at 2.4 mg weekly. The active compound in both is identical: semaglutide. The comparison below applies to semaglutide generally.

The mechanism and efficacy differences described in the semaglutide section above apply here. In everyday search and clinical discussion, "tirzepatide vs Ozempic" is the most common framing because Ozempic has the highest brand recognition of the GLP-1 class despite Wegovy being the weight-management-indicated product.

From a research standpoint, comparing tirzepatide to Ozempic-dose semaglutide (1 mg) is comparing it to a lower dose than the highest-approved semaglutide dose. Researchers studying relative efficacy should specify which semaglutide dose and indication context is being referenced.

Key points for researchers:

• Tirzepatide's dual GIP/GLP-1 mechanism vs semaglutide's single GLP-1 mechanism is the fundamental structural distinction.
• Both have weekly dosing intervals and similar half-lives.
• SURPASS-2 provides the most direct comparator data (tirzepatide vs semaglutide 1 mg, T2D population).
• No direct head-to-head trial of tirzepatide vs semaglutide 2.4 mg in an obesity population had been completed as of June 2026 [verify before publish].

Tirzepatide vs Retatrutide#

Retatrutide is a triple agonist at GIP, GLP-1, and glucagon receptors (GCGR). It is not FDA-approved as of June 2026 and is only available as a research-grade compound through peptide suppliers.

Mechanism comparison. Tirzepatide = GIP + GLP-1 (dual). Retatrutide = GIP + GLP-1 + glucagon (triple). The addition of glucagon receptor agonism in retatrutide is hypothesized to further accelerate energy expenditure and fat mobilization, complementing the insulin-sensitizing and appetite-suppressing effects of GIP/GLP-1 co-agonism.

Trial data available. Phase 2 data for retatrutide was published in 2023, reporting mean weight reductions of approximately 17.5% at 48 weeks at 12 mg doses in adults with obesity — greater than any GLP-1-only compound in comparable timeframes and comparable to or exceeding tirzepatide SURMOUNT results on shorter timelines (Jastreboff et al., NEJM 2023). Phase 3 results were not yet published as of June 2026.

What researchers are watching. The triple-agonist approach is the current frontier in GLP-1-adjacent peptide research. Retatrutide's Phase 2 results attracted substantial attention because the rate and magnitude of weight reduction appeared to exceed tirzepatide at comparable dose levels and timeframes, though direct head-to-head comparison in a single trial does not yet exist.

Key differences for sourcing.

• Tirzepatide is FDA-approved (Mounjaro/Zepbound); retatrutide is not.
• Tirzepatide has an extensive Phase 3 safety database; retatrutide's safety data is Phase 2-limited.
• Both are available from research-grade peptide vendors; tirzepatide is more widely stocked.
• Retatrutide research-grade material tends to be available in fewer vial sizes and from fewer suppliers.

For a full comparison, see our retatrutide guide and vendor review.

Compounded Tirzepatide vs Brand vs Research-Grade: FDA 503A/503B Status (2026)#

The Three Categories#

Brand tirzepatide (Mounjaro / Zepbound) is the Eli Lilly pharmaceutical product, manufactured under full FDA pharmaceutical GMP oversight, dispensed by licensed pharmacies under valid prescriptions, and subject to post-market safety surveillance. This is the only FDA-approved form.

Compounded tirzepatide is prepared by compounding pharmacies under 503A or 503B designation. The legal access pathway changed significantly in 2025.

Research-grade tirzepatide is synthesized by peptide chemistry vendors and sold for laboratory research purposes only. It is not dispensed under any prescription and is not regulated as a drug product.

FDA 503A/503B Compounding Status — 2025–2026#

The landscape for compounded tirzepatide shifted materially in 2025. The FDA had placed tirzepatide on the drug shortage list beginning in late 2022, which created the legal basis for 503A and 503B compounding pharmacies to compound it at scale. When the FDA removed tirzepatide from the shortage list, the basis for mass compounding changed.

The key regulatory developments as of our June 2026 review date:

• 503B outsourcing facilities (large-scale compounders supplying healthcare facilities) faced a phased enforcement deadline to cease mass-producing compounded tirzepatide after removal from the shortage list. The FDA's withdrawal of enforcement discretion for 503B bulk compounding was a major market disruption for telehealth programs that relied on outsourcing facilities.
• 503A pharmacies (patient-specific compounding) may still compound tirzepatide for individual patients with a valid prescription under qualifying conditions — primarily when a licensed prescriber documents a clinical need not met by the commercially available product (e.g., a specific dose strength or formulation). This remains an evolving and state-dependent regulatory area.
• Telehealth platforms that offered compounded tirzepatide through 503B supply chains have faced product availability challenges since the restrictions took effect.

Implications for Sourcing#

Patients seeking compounded tirzepatide should consult a licensed prescriber and confirm that their compounding pharmacy is 503A-accredited and operating within current FDA guidance. Patients seeking the brand product should use the standard prescription pathway through an endocrinologist, primary care physician, or telehealth prescriber.

Research labs sourcing tirzepatide peptide for research applications fall outside this regulatory framework — research-grade peptide is not a compounded drug and is not subject to the 503A/503B rules. It is governed by the vendor's quality controls and the buyer's research-use obligations.

For current research-grade sourcing options, see Tirzepatide and compare vendors on our where-to-buy page.

Frequently Asked Questions

Research-Use Disclaimer#

This guide is for educational and research reference only. Tirzepatide is FDA-approved only as prescription Mounjaro and Zepbound, dispensed under medical supervision. Research-grade tirzepatide peptide from the vendors referenced here is for in-vitro laboratory research only — not for human consumption, self-administration, or use as a substitute for any prescription drug. Nothing in this guide constitutes medical advice, a treatment recommendation, or a dosing instruction. If you are a patient seeking treatment with tirzepatide, consult a licensed healthcare provider.

Last reviewed: June 2026. For research and educational purposes only.